Gerald E. Archer

1.7k total citations · 1 hit paper
28 papers, 1.3k citations indexed

About

Gerald E. Archer is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Gerald E. Archer has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 12 papers in Oncology and 10 papers in Genetics. Recurrent topics in Gerald E. Archer's work include Immunotherapy and Immune Responses (13 papers), Glioma Diagnosis and Treatment (10 papers) and CAR-T cell therapy research (5 papers). Gerald E. Archer is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), Glioma Diagnosis and Treatment (10 papers) and CAR-T cell therapy research (5 papers). Gerald E. Archer collaborates with scholars based in United States, Australia and Norway. Gerald E. Archer's co-authors include Darell D. Bigner, John H. Sampson, Henry S. Friedman, David A. Reardon, Thomas F. Tedder, Smita K. Nair, Roger E. McLendon, Amy B. Heimberger, James E. Herndon and Michael R. Zalutsky and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Biochemical and Biophysical Research Communications.

In The Last Decade

Gerald E. Archer

27 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

2015 313 citations James M. Schuster, Lawrence D. Recht et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald E. Archer United States	14	629	609	545	357	236	28	1.3k
Chien‐Tsun Kuan United States	23	655 1.0×	245 0.4×	442 0.8×	734 2.1×	468 2.0×	37	1.6k
Elias Sayour United States	25	1000 1.6×	531 0.9×	962 1.8×	657 1.8×	99 0.4×	81	2.0k
Ezogelin Oflazoglu United States	18	809 1.3×	149 0.2×	703 1.3×	463 1.3×	727 3.1×	23	1.7k
Tina Verschuere Belgium	17	404 0.6×	273 0.4×	641 1.2×	307 0.9×	36 0.2×	21	1.0k
John T. Kemshead United Kingdom	18	437 0.7×	133 0.2×	225 0.4×	464 1.3×	233 1.0×	35	1.2k
Jie Qing Chen United States	8	637 1.0×	305 0.5×	481 0.9×	257 0.7×	31 0.1×	15	994
Mihaela Lorger United Kingdom	17	523 0.8×	275 0.5×	207 0.4×	492 1.4×	51 0.2×	29	1.2k
Christian J. Davidson United States	9	227 0.4×	422 0.7×	178 0.3×	383 1.1×	67 0.3×	17	930
Yoshihiro Otani Japan	15	329 0.5×	200 0.3×	95 0.2×	373 1.0×	186 0.8×	65	853

Countries citing papers authored by Gerald E. Archer

Since Specialization

Citations

This map shows the geographic impact of Gerald E. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald E. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald E. Archer more than expected).

Fields of papers citing papers by Gerald E. Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald E. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald E. Archer. The network helps show where Gerald E. Archer may publish in the future.

Co-authorship network of co-authors of Gerald E. Archer

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald E. Archer. A scholar is included among the top collaborators of Gerald E. Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald E. Archer. Gerald E. Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thompson, Eric M., David M. Ashley, Pamela K. Norberg, et al.. (2024). Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2039–2039. 4 indexed citations

Hotchkiss, Kelly, Kristen A. Batich, Gerald E. Archer, et al.. (2021). IMMU-04. VACCINATING AGAINST NOVEL CYTOMEGALOVIRUS ANTIGENS IN GLIOBLASTOMA USING A PEPTIDE VACCINE IN COMBINATION WITH TEMOZOLOMIDE. Neuro-Oncology Advances. 3(Supplement_4). iv5–iv5. 1 indexed citations

Peters, Katherine B., Gerald E. Archer, Pamela K. Norberg, et al.. (2019). Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology. 37(15_suppl). e13526–e13526. 11 indexed citations

Atik, Ahmet, Carter M. Suryadevara, Ryan M. Schweller, et al.. (2018). Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience. 56. 163–168. 45 indexed citations

Dunn‐Pirio, Anastasie, Katherine B. Peters, Annick Desjardins, et al.. (2017). Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial (S41.004). Neurology. 88(16_supplement). 4 indexed citations

Saraswathula, Anirudh, Elizabeth A. Reap, Bryan D. Choi, et al.. (2016). Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology Immunotherapy. 65(2). 205–211. 6 indexed citations

Vlahovic, Gordana, Gerald E. Archer, Elizabeth A. Reap, et al.. (2016). Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology. 34(15_suppl). e13518–e13518. 10 indexed citations

Schuster, James M., Lawrence D. Recht, David A. Reardon, et al.. (2015). A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology. 17(6). 854–861. 313 indexed citations breakdown →

Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, et al.. (2014). Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology. 32(15_suppl). 3069–3069.

10.

Sánchez-Pérez, Luis, Bryan D. Choi, Elizabeth A. Reap, et al.. (2013). BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology Immunotherapy. 62(6). 983–987. 13 indexed citations

11.

Nair, Smita K., Gerald E. Archer, & Thomas F. Tedder. (2012). Isolation and Generation of Human Dendritic Cells. Current Protocols in Immunology. 99(1). 7.32.1–7.32.23. 113 indexed citations

12.

Sampson, John H., Kenneth Aldape, Gerald E. Archer, et al.. (2010). Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13(3). 324–333. 279 indexed citations

13.

Sampson, John H., Gamal Akabani, Gerald E. Archer, et al.. (2008). Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10(3). 320–329. 145 indexed citations

14.

Kurpad, Shekar N., M. Eileen Dolan, Roger E. McLendon, et al.. (1997). Intraarterial O 6 -benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39(4). 307–316. 22 indexed citations

15.

Zalutsky, Michael R., James M. Schuster, Pradeep Garg, et al.. (1996). Two Approaches for Enhancing Radioimmunotherapy: ∝ Emitters and Hyperthermia. Recent results in cancer research. 141. 101–122. 10 indexed citations

16.

McLendon, Roger E., Gerald E. Archer, Pradeep Garg, Darell D. Bigner, & Michael R. Zalutsky. (1996). Radiotoxicity of systemically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: A long-term survival study with histologic analysis. International Journal of Radiation Oncology*Biology*Physics. 35(1). 69–80. 19 indexed citations

17.

Wikstrand, Carol J., Sydney Stanley, Peter A. Humphrey, et al.. (1993). Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. Journal of Neuroimmunology. 46(1-2). 165–173. 24 indexed citations

18.

Humphrey, Peter A., Lisa M. Gangarosa, Albert J. Wong, et al.. (1991). Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function. Biochemical and Biophysical Research Communications. 178(3). 1413–1420. 80 indexed citations

19.

Fuchs, Herbert E., Gerald E. Archer, O. Michael Colvin, et al.. (1990). Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.. PubMed. 50(6). 1954–9. 44 indexed citations

20.

Garg, Pradeep, Gerald E. Archer, D D Bigner, & Michael R. Zalutsky. (1989). Synthesis of radioiodinated N-succinimidyl iodobenzoate: Optimization for use in antibody labelling. International Journal of Radiation Applications and Instrumentation Part A Applied Radiation and Isotopes. 40(6). 485–490. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact